AMRN has a major clinical trial release date of Q3. Drug could overtake Lovaza. Thoughts?

This is a phase 4 study looking for CV outcomes in a multicenter study. Other cholesterol drugs look at labs, not outcomes, so if this study comes back with significant results, I see AMRN getting a bump. Thoughts?

Submitted July 06, 2018 at 04:22PM by daviddavidson29 https://ift.tt/2MQGTFt